Fine-tuning miR-21 expression and inhibition of EMT in breast cancer cells using aromatic-neomycin derivatives

Ghosh, Arpita; Ranjan, Nihar; Jiang, Liuwei; Ansari, Asgar Hussain; Degyterava, Natalya; Ahluwalia, Shivaksh; Arya, Dev P.; Maiti, Souvik

doi:10.1016/j.omtn.2021.12.027

Cited by 10 publications

(4 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 47 ] In contrast, both miR‐21 and miR‐10a are highly expressed in tumor cells under EMT. [ 48,49 ] The miRNA‐based Nano‐DMFC could achieve higher accuracy by detecting these EpCAM‐negative CTCs. Second, the single‐cell droplet‐based Nano‐DMFC platform could perform single‐cell analysis in the isolated droplets, which could avoid the interference from other cells and the bulk solution.…”

Section: Resultsmentioning

confidence: 99%

2D MOF Nanosensor‐Integrated Digital Droplet Microfluidic Flow Cytometry for In Situ Detection of Multiple miRNAs in Single CTC Cells

Chen

Oudeng

Feng

et al. 2022

Small

View full text Add to dashboard Cite

Current circulating tumor cells (CTCs) detection strategies based on surface epithelial markers suffer from low specificity in distinguishing between CTCs and epithelial cells in hematopoietic cell population. Tumor‐associated miRNAs within CTCs are emerging as new biomarkers due to their high correlation with tumor development and progress. However, in‐situ simultaneous analysis of multiple miRNAs in single CTC cell is still challenging. To overcome this limitation, a digital droplet microfluidic flow cytometry based on biofunctionalized 2D metal‐organic framework nanosensor (Nano‐DMFC) is developed for in situ detection of dual miRNAs simultaneously in single living breast cancer cells. Here, 2D MOF‐based fluorescent resonance energy transfer (FRET) nanosensors are established by conjugating dual‐color fluorescence dye‐labeled DNA probes on MOF nanosheet surface. In the Nano‐DMFC, 2D MOF‐based nanoprobes are precisely microinjected into each single‐cell encapsulated droplets to achieve dual miRNA characterization in single cancer cell. This Nano‐DMFC platform successfully detects dual miRNAs at single‐cell resolution in 10 mixed positive MCF‐7 cells out of 10 000 negative epithelial cells in serum biomimic samples. Moreover, this Nano‐DMFC platform shows good reproductivity in the recovery experiment of spiked blood samples, which demonstrate the high potential for CTC‐based cancer early diagnosis and prognosis.

show abstract

Section: Resultsmentioning

confidence: 99%

2D MOF Nanosensor‐Integrated Digital Droplet Microfluidic Flow Cytometry for In Situ Detection of Multiple miRNAs in Single CTC Cells

Chen

Oudeng

Feng

et al. 2022

Small

View full text Add to dashboard Cite

show abstract

“…More specifically, miR‐21 and its precursor pre‐miR‐21 (Figure 1a) have been in the spotlight after its consistent overexpression has recently been reported in a study profiling 540 clinical samples from cancer patients [8] . The inhibition of miR‐21 function thus holds the promise for both efficient therapy alone, [9a–f] and as an adjuvant to the existing treatments [10a–e] . The search for small molecule inhibitors of miR‐21 is mainly based on the targeting of one of its precursors (pri‐ or pre‐miRNA) that bear secondary structures formed by the presence of single‐stranded regions (loop and bulges) that together with double‐stranded ones induce the formation of specific RNA binding pockets (Figure 1a).…”

Section: Introductionmentioning

confidence: 93%

De‐Novo Design of pre‐miR‐21 Maturation Inhibitors: Synthesis and Activity Assessment

Shcheholeva

Fernández-Remacha

Estrada‐Tejedor

et al. 2023

Chemistry A European J

View full text Add to dashboard Cite

Targeting RNA with small molecules is a major challenge of current medicinal chemistry, and the identification and design of original scaffolds able to selectively interact with an RNA target remains difficult. Various approaches have been developed based on classical medicinal chemistry strategies (fragment-based drug design, dynamic combinatorial chemistry, HTS or DNA-encoded libraries) as well as on advanced structural biology and biochemistry methodologies (such as X-ray, cryo-EM, NMR, or SHAPE). Here, we report the de novo design, synthesis, and biological evaluation of RNA ligands by using a straightforward and sustainable chemistry combined with molecular docking and biochemical and biophysical studies that allowed us to identify a novel pharmacophore for RNA binding. Specifically, we focused on targeting the biogenesis of microRNA-21, the well-known oncogene. This led us not only to promising inhibitors but also to a better understanding of the interactions between the small-molecule compounds and the RNA target paving the way for the rational design of efficient inhibitors with potential anticancer activity.

show abstract

“…Onco-miRNAs that are firmly established include the miR-17-92 cluster, which is situated in intron 3 of the C13orf25 gene at 13q31.3 and is overexpressed in lung cancer. 118 Overexpression of miR-21 has been observed in liver, 119 stomach, 120 breast, 121 and ovarian cancer. 122 While miR-181 is upregulated in oral squamous cell carcinoma, breast cancer, prostate cancer, and gastric cancer.…”

Section: Effect Of Mirnas In Cancer and Cancer Therapymentioning

confidence: 99%

The Role of microRNAs in Hepatocellular Cancer: A Narrative Review Focused on Tumor Microenvironment and Drug Resistance

Tavakoli Pirzaman,

Alishah,

Babajani

et al. 2024

Technol Cancer Res Treat

View full text Add to dashboard Cite

Globally, hepatic cancer ranks fourth in terms of cancer-related mortality and is the sixth most frequent kind of cancer. Around 80% of liver cancers are hepatocellular carcinomas (HCC), which are the leading cause of cancer death. It is well known that HCC may develop resistance to the available chemotherapy treatments very fast. One of the biggest obstacles in providing cancer patients with appropriate care is drug resistance. According to reports, more than 90% of cancer-specific fatalities are caused by treatment resistance. By binding to the 3'-untranslated region of target messenger RNAs (mRNAs), microRNAs (miRNAs), a group of noncoding RNAs which are around 17 to 25 nucleotides long, regulate target gene expression. Moreover, they play role in the control of signaling pathways, cell proliferation, and cell death. As a result, miRNAs play an important role in the microenvironment of HCC by changing immune phenotypes, hypoxic conditions, and acidification, as well as angiogenesis and extracellular matrix components. Moreover, changes in miRNA levels in HCC can effectively resist cancer cells to chemotherapy by affecting various cellular processes such as autophagy, apoptosis, and membrane transporter activity. In the current work, we narratively reviewed the role of miRNAs in HCC, with a special focus on tumor microenvironment and drug resistance.

show abstract

Fine-tuning miR-21 expression and inhibition of EMT in breast cancer cells using aromatic-neomycin derivatives

Cited by 10 publications

References 66 publications

2D MOF Nanosensor‐Integrated Digital Droplet Microfluidic Flow Cytometry for In Situ Detection of Multiple miRNAs in Single CTC Cells

2D MOF Nanosensor‐Integrated Digital Droplet Microfluidic Flow Cytometry for In Situ Detection of Multiple miRNAs in Single CTC Cells

De‐Novo Design of pre‐miR‐21 Maturation Inhibitors: Synthesis and Activity Assessment

The Role of microRNAs in Hepatocellular Cancer: A Narrative Review Focused on Tumor Microenvironment and Drug Resistance

Contact Info

Product

Resources

About